NCT05121376: An ongoing trial by BioMarin Pharmaceutical
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05121376 |
|---|---|
| Title | A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 15, 2022 |
| Completion date | Nov. 30, 2028 |
| Required reporting date | Nov. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |